Key Segments:
By Product
-
Embolectomy Balloon Catheters
-
Catheter-Directed Thrombolysis Devices
-
Mechanical/Percutaneous Thrombectomy Devices
-
Inferior Vena Cava (IVC) Filters
-
Neurovascular Embolectomy/Thrombectomy Devices
By End User
-
Hospitals
-
Ambulatory Surgical Centers (ASCs)
-
Specialty Clinics
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Russia
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Key players include Boston Scientific, Penumbra, Stryker (Inari Medical), Medtronic, Johnson & Johnson MedTech (Cerenovus), Terumo, Teleflex, and AngioDynamics.
Key opportunities include super-bore and computer-assisted aspiration platforms, medium-vessel occlusion devices, pulmonary embolism thrombectomy, and emerging-market stroke care expansion.
The market is driven by the rising thromboembolic disease burden, the shift from open surgery and thrombolysis to endovascular therapy, expanding stroke treatment evidence, and aging populations.
The Neurovascular Embolectomy/Thrombectomy Devices segment dominated the Clot Management Devices Market, accounting for approximately 35% market share.
The North America region dominated the Clot Management Devices Market in 2025 with approximately 42.8% share, driven by high stroke and VTE burden, strong reimbursement, and an extensive stroke centre network.
